{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/migraine/prescribing-information/drugs-for-acute-migraine/","result":{"pageContext":{"chapter":{"id":"d1661673-77b9-587b-94ce-e5b6ff9de8c5","slug":"drugs-for-acute-migraine","fullItemName":"Drugs for acute migraine","depth":2,"htmlHeader":"<!-- begin field 9c171544-b9e5-40d4-8212-aa2301028d65 --><h2>Drugs for acute migraine</h2><!-- end field 9c171544-b9e5-40d4-8212-aa2301028d65 -->","summary":"","htmlStringContent":"<!-- begin item c0c24dee-f8fd-45f0-b01f-aa2301028d1e --><!-- end item c0c24dee-f8fd-45f0-b01f-aa2301028d1e -->","topic":{"id":"b2a19577-fc3a-5b75-948b-7c86424dba8f","topicId":"8d5c9fe8-c317-4160-9aa5-50f3a0456472","topicName":"Migraine","slug":"migraine","lastRevised":"Last revised in October 2020","chapters":[{"id":"f5de766d-b899-5cb2-978f-7194e0cbeaf4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"57045461-bc73-53e8-9968-49ab778a037a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"32406f3a-91ba-5801-9ef0-87ad7d9b3133","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"52e6d993-e2b2-59c3-920f-27f34a7ec2eb","slug":"changes","fullItemName":"Changes"},{"id":"9560b149-423e-5bf5-8239-ae3f4bc97616","slug":"update","fullItemName":"Update"}]},{"id":"f6c897d2-fd52-5c54-a91b-1b366dced50e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"058608e6-7b11-54ed-9d12-69b94ea020cf","slug":"goals","fullItemName":"Goals"},{"id":"95d8aa4b-0bce-5da9-b56a-a612d637a001","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f9b5443b-1c38-5f3c-be42-3e7fffa429e3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5644cb5-763c-596c-8c47-919fec89ce47","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"92308844-16f7-5eeb-9c0a-ad97a07896ec","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b97a29bb-bac7-5bc8-907c-210d887086f2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"986db6f6-7568-5e6e-8095-5ce116d22307","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"b6d1719e-8f6a-509b-90d2-7d1f38e19b05","slug":"definition","fullItemName":"Definition"},{"id":"e35d9975-5859-5454-9539-fab1a8ca6a43","slug":"causes","fullItemName":"Causes"},{"id":"3d8350c0-8bc5-5793-a577-411bc703d36f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"eea7fb2e-ce45-5fa7-9ff5-5399f8305dd7","slug":"prognosis","fullItemName":"Prognosis"},{"id":"ad3ec7a1-a418-5232-b554-b202784e3f46","slug":"complications","fullItemName":"Complications"}]},{"id":"23b2a2ec-5694-51eb-97af-5e80f8d0b792","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"86e96919-af81-53dc-805a-36533fa27637","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"1b00b35a-f7c5-5dc3-bd7d-6e72a973af14","slug":"assessment","fullItemName":"Assessment"},{"id":"33c2a435-70da-50e9-b336-2d81b68f99c9","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1ece6bbf-1986-5392-be1d-427e9603f26a","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb14162e-c87a-5ca7-8eda-4acb5c336298","slug":"adults","fullItemName":"Scenario: Adults"},{"id":"3bced75d-3a79-536f-976d-875a40bf1a8d","slug":"young-people-aged-12-17-years","fullItemName":"Scenario: Young people aged 12-17 years"},{"id":"604f5c24-3920-5626-893b-9c27575decc6","slug":"pregnant-or-breastfeeding-women","fullItemName":"Scenario: Pregnant or breastfeeding women"}]},{"id":"8e2844f3-6843-5776-a5a1-59b0cabc5b93","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d1661673-77b9-587b-94ce-e5b6ff9de8c5","slug":"drugs-for-acute-migraine","fullItemName":"Drugs for acute migraine"},{"id":"b69cd3a2-8118-552d-ba35-c7db1a498617","slug":"drugs-for-the-prevention-of-migraine","fullItemName":"Drugs for the prevention of migraine"}]},{"id":"daf55050-4154-5b6d-b8ab-0f86775d1038","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0fbeb3e2-26df-5d63-a045-8af31aed07ef","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"88a22f7c-7eb4-5b57-a406-ab204723d6c0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"596ed3f2-0ac4-5fd9-9046-b304311543ee","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"c4597510-7ec3-5f98-b5a5-3ef55cd51b5e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"79a12dcb-038c-5fd4-a311-648c3ee61102","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"41030681-d726-58c4-b509-29748e404597","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"9a8a7e48-db76-50eb-a585-96fe1b4a5977","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"8e2844f3-6843-5776-a5a1-59b0cabc5b93","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"b1946e53-0068-51cc-92bb-6224dcb36739","slug":"paracetamol","fullItemName":"Paracetamol","depth":3,"htmlHeader":"<!-- begin field 72a68f77-48c2-4836-a752-aa230102aa24 --><h3>Paracetamol</h3><!-- end field 72a68f77-48c2-4836-a752-aa230102aa24 -->","summary":"","htmlStringContent":"<!-- begin item 5cb62756-3b7b-4527-93da-aa230102a9f8 --><!-- begin field ca7d5cfd-cb9f-47f3-9704-aa230102aa24 --><ul><li>For detailed prescribing information on paracetamol, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li></ul><!-- end field ca7d5cfd-cb9f-47f3-9704-aa230102aa24 --><!-- end item 5cb62756-3b7b-4527-93da-aa230102a9f8 -->","subChapters":[]},{"id":"4bb9dfdb-e9df-5a3c-9658-80b36d8a740a","slug":"nonsteroidal-anti-inflammatories","fullItemName":"Nonsteroidal anti-inflammatories","depth":3,"htmlHeader":"<!-- begin field c8d18814-3751-4516-81cb-aa230102c5a6 --><h3>Nonsteroidal anti-inflammatories</h3><!-- end field c8d18814-3751-4516-81cb-aa230102c5a6 -->","summary":"","htmlStringContent":"<!-- begin item 89f65487-7603-476e-80d8-aa230102be70 --><!-- begin field ef3a1199-f8bd-4c07-8fb9-aa230102c5a6 --><ul><li>For detailed prescribing information on nonsteroidal anti-inflammatory drugs (NSAIDs), see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a> and <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>.</li></ul><!-- end field ef3a1199-f8bd-4c07-8fb9-aa230102c5a6 --><!-- end item 89f65487-7603-476e-80d8-aa230102be70 -->","subChapters":[]},{"id":"d04e74e9-f2e9-50ae-b07f-456ba2d86162","slug":"aspirin","fullItemName":"Aspirin","depth":3,"htmlHeader":"<!-- begin field 567825ba-f57b-4895-8ecb-aa230102d11d --><h3>Aspirin</h3><!-- end field 567825ba-f57b-4895-8ecb-aa230102d11d -->","summary":"","htmlStringContent":"<!-- begin item 20b89c60-2c00-4fcc-885c-aa230102d0e3 --><!-- begin field 6430c174-00cc-45ba-bede-aa230102d11d --><ul><li>For detailed prescribing information on aspirin, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li></ul><!-- end field 6430c174-00cc-45ba-bede-aa230102d11d --><!-- end item 20b89c60-2c00-4fcc-885c-aa230102d0e3 -->","subChapters":[]},{"id":"de0833e4-ea0e-5995-b09b-890da81cdb71","slug":"triptans","fullItemName":"Triptans","depth":3,"htmlHeader":"<!-- begin field 60f2e94f-4801-43e6-b3c7-aa23010336b1 --><h3>Triptans</h3><!-- end field 60f2e94f-4801-43e6-b3c7-aa23010336b1 -->","summary":"","htmlStringContent":"<!-- begin item 6b168552-5d4c-4654-a5e2-aa230103368e --><!-- begin field 9b0c730c-bd24-46db-844a-aa23010336b1 --><ul><li>The Scottish Intercollegiate Guidelines Network (SIGN) recommend sumatriptan (50–100 mg) as first choice of triptan in acute migraine for most people.<ul><li>An alternative triptan should be tried if initial choice proves ineffective.</li><li>Other triptans available for treating migraine include almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, and zolmitriptan.</li></ul></li><li>If vomiting restricts oral treatment, a non-oral formulation, such as intranasal spray or subcutaneous injection should be considered.<ul><li>‘Melt' preparations which dissolve in the mouth are gastrically absorbed and not categorised as non-oral preparations.</li></ul></li><li>Sumatriptan nasal spray (10mg) is the only triptan licensed for use in young people aged 12 years or older.<ul><li>The manufacturer advises that use of sumatriptan in adolescents should be on the recommendation of a specialist or physician with significant experience in treating migraine, taking into account local guidance.</li></ul></li><li>Triptans are not licensed for people aged over 65 years.</li></ul><h4>Contraindications and cautions</h4><ul><li><strong>Do not prescribe triptans to people:</strong><ul><li>With cardiovascular disorders including ischaemic heart disease, hypertension, previous myocardial infarction, coronary vasospasm, arrhythmias or peripheral vascular disease.</li><li>With cerebrovascular disorders including previous transient ischaemic attack or cerebrovascular accident.</li><li>With severe hepatic impairment.</li><li>Concurrently with other triptans, monoamine oxidase inhibitors or ergotamine (or its derivatives).</li></ul></li><li><strong>Prescribe with caution in people:</strong><ul><li>With risk factors for cardiovascular disease — cardiovascular assessment required prior to prescription.</li><li>Who are elderly (unlicensed).</li><li>With a history of, or risk factors for, seizures.</li><li>With renal or hepatic impairment — dose adjustment may be required.</li></ul></li></ul><h4>Adverse effects</h4><ul><li><strong>Adverse effects include:</strong><ul><li>Nervous system disorders — dizziness and drowsiness.</li><li>Respiratory disorders — dyspnoea.</li><li>Gastrointestinal disorders — nausea and vomiting, dysphagia. Intestinal ischemia has been reported with almotriptan.</li><li>Skin and musculoskeletal disorders — myalgia.</li><li>Other general adverse effects — flushing, fatigue, feeling abnormal, pain and sensations of heat or cold.</li><li>With intranasal use — epistaxis, nasal irritation, altered taste and throat irritation.</li><li>With subcutaneous use — haemorrhage, skin reactions and swelling.</li></ul></li><li>Advise the person to seek medical advice and discontinue if symptoms of heat, heaviness, pressure or tightness (including throat and chest) occur.</li><li>Drowsiness may affect performance of skilled tasks (such as driving).</li></ul><h4>Drug interactions</h4><ul><li><strong>Concomitant use is contraindicated with:</strong><ul><li>Monoamine oxidase inhibitors, or within 2 weeks of stopping a monoamine oxidase inhibitor.</li><li>Ergotamine or derivatives of ergotamine, including methysergide — increased risk of vasoconstriction.</li><li>CYP3A4 inhibitors (such as clarithromycin, erythromycin, ketoconazole, itraconazole, indinavir, nelfinavir, ritonavir) for eletriptan.</li><li>Other triptans — manufacturer advises waiting at least 24 hours following the use of one triptan before changing to an alternative triptan.</li></ul></li><li>Triptans should be used with caution in people taking selective serotonin reuptake inhibitors (SSRIs), selective noradrenaline reuptake inhibitors (SNRIs), lithium, sibutramine, ondansetron or St John's wort (because of the small risk of serotonin syndrome).</li><li>The maximum dose of rizatriptan in people who are also taking propranolol should be 5 mg due to the risk of interactions — rizatriptan should not be taken within two hours of taking propranolol.</li></ul><h4>Pregnancy and breastfeeding</h4><ul><li><strong>Pregnancy</strong><ul><li>There is limited experience of using triptans during pregnancy.</li><li>Manufacturer recommends avoiding unless the potential benefit outweighs risk.</li></ul></li><li><strong>Breast feeding</strong><ul><li>Present in milk but amount probably too small to be harmful.</li><li>Manufacturer recommends minimising infant exposure by avoiding breast feeding for 12 hours after treatment, during which time any breast milk expressed should be discarded.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Becker, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2019a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 9b0c730c-bd24-46db-844a-aa23010336b1 --><!-- end item 6b168552-5d4c-4654-a5e2-aa230103368e -->","subChapters":[]},{"id":"c0c88194-77df-5802-9540-8906b8d1ed3e","slug":"anti-emetics","fullItemName":"Anti-emetics","depth":3,"htmlHeader":"<!-- begin field 40393a81-f367-4136-83e4-aa230103c599 --><h3>What should I be aware of before prescribing metoclopramide or prochlorperazine?</h3><!-- end field 40393a81-f367-4136-83e4-aa230103c599 -->","summary":"","htmlStringContent":"<!-- begin item ee807a17-2d14-45a8-9897-aa230103c56f --><!-- begin field 6b0fafd9-e6f3-4c97-bf9e-aa230103c599 --><p>Clinical guidelines from the National Institute for Health and Care Excellence and the Scottish Intercollegiate Guidelines Network (SIGN) state that metoclopramide (10 mg) or prochlorperazine (10 mg) can be considered in the treatment of migraine associated headache, nausea or vomiting.</p><ul><li><strong>Metoclopramide</strong><ul><li>Metoclopramide is used in the treatment of acute migraine, but is not licensed for this indication.</li><li>Metoclopramide should not be used regularly due to the risk of extrapyramidal side effects and only be prescribed for short-term use.</li></ul></li><li><strong>Prochlorperazine</strong><ul><li>Prochlorperazine as a buccal tablet can be used for nausea and vomiting in previously diagnosed migraine in people aged over 12 years.</li></ul></li></ul><h4>Contraindications</h4><ul><li><strong>Do not prescribe metoclopramide to people with:</strong><ul><li>Gastrointestinal haemorrhage, obstruction, perforation or recent surgery.</li><li>Phaeochromocytoma — risk of severe hypertension.</li><li>Neurological disorders such as epilepsy and Parkinson’s disease.</li></ul></li><li><strong>Do not prescribe prochlorperazine to people with:</strong><ul><li>CNS depression.</li><li>Phaeochromocytoma.</li><li>Liver or renal dysfunction.</li><li>Neurological disorders such as epilepsy Parkinson’s disease.</li><li>Cardiovascular disorders such as QT prolongation or heart failure — consider ECG.</li></ul></li></ul><h4>Cautions</h4><ul><li><strong>Prescribe metoclopramide with caution in</strong><ul><li>Children, young adults (15–19 years old) and the elderly.</li><li>Renal or hepatic impairment.</li><li>Cardiac disorders such as cardiac conduction disturbances, uncorrected electrolyte imbalance and bradycardia.</li></ul></li><li><strong>Prescribe prochlorperazine with caution in</strong>:<ul><li>The elderly.</li><li>Hypothyroidism.</li><li>Renal impairment.</li><li>People with cardiovascular risk factors.</li></ul></li></ul><h4>Adverse effects</h4><ul><li><strong>Metoclopramide</strong><ul><li>Metoclopramide can induce acute dystonic reactions (facial and skeletal muscle spasms and oculogyric crises) — more common in younger people (especially girls and young women) and the very old.</li><li>Common adverse effects include diarrhoea, asthenia, drowsiness, depression, and hypotension.</li></ul></li><li><strong>Prochlorperazine</strong><ul><li>Prochlorperazine can cause sedation and extrapyramidal adverse effects (especially dystonia) — likely to be mild with occasional low-dose use.<ul><li>Warn the person about drowsiness during the early days of treatment and advised not to drive or operate machinery.</li></ul></li><li>Other adverse effects include blood disorders, endocrine disorders, insomnia and agitation, hyponatraemia, SADH, skin reactions, cardiac disorders, jaundice, muscle rigidity, nasal congestion and respiratory depression.<ul><li>Neuroleptic malignant syndrome (hyperthermia, rigidity, autonomic dysfunction and altered consciousness) may occur with any neuroleptic drug.</li></ul></li></ul></li></ul><h4>Drug interactions</h4><ul><li><strong>Metoclopramide</strong><ul><li>Levodopa or dopaminergic agonists — may reduce effectiveness.</li><li>Alcohol — potentiates the sedative effect of metoclopramide.</li><li>Central nervous system depressants (such as morphine derivatives, anxiolytics, sedative antihistamines, sedative antidepressants, barbiturates, clonidine) — sedative effects potentiated.</li><li>Serotinergic drugs — may increase the risk of serotonin syndrome.</li></ul></li><li><strong>Prochlorperazine</strong><ul><li>Alcohol — increased risk of hypotension and CNS depression.</li><li>Amitriptyline — increased risk of hypotension.</li><li>Anti-hypertensives — increased risk of hypotension.</li><li>CNS depressants — may affect the ability to perform skilled tasks.</li><li>Cabergoline, levo-dopa and ropinerole — may reduce effectiveness.</li><li>QT prolonging drugs — increased risk of arrhythmias.</li><li>Carbamazepine and other drugs with myelosuppressive potential — increased risk of agranulocytosis.</li></ul></li></ul><h4>Pregnancy and breastfeeding</h4><ul><li><strong>Pregnancy</strong><ul><li><strong>Metoclopramide</strong> — not known to be harmful.<ul><li>Manufacturer recommends avoid at the end of pregnancy as extrapyramidal syndrome in newborn cannot be excluded.</li><li>For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nausea-vomiting-in-pregnancy/\">Nausea/vomiting in pregnancy</a>.</li></ul></li><li><strong>Prochlorperazine</strong><ul><li>Manufacturer advises avoid unless benefits outweigh risks.</li><li>Extrapyramidal effects and withdrawal syndrome have been reported occasionally in the neonate when antipsychotic drugs are taken during the third trimester of pregnancy.</li></ul></li></ul></li><li><strong>Breastfeeding</strong><ul><li><strong>Metoclopramide</strong>.<ul><li>Small amount present in milk.</li><li>Manufacturer recommends avoid.</li></ul></li><li><strong>Prochlorperazine</strong>.<ul><li>Limited data available, animal studies indicate possible adverse effects of antipsychotic medicines on the developing nervous system.</li><li>Manufacturer recommends avoid.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">NICE, 2012 (updated 2015)</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">SIGN, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">ABPI, 2019c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/migraine/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 6b0fafd9-e6f3-4c97-bf9e-aa230103c599 --><!-- end item ee807a17-2d14-45a8-9897-aa230103c56f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}